Arks gains NHS reimbursement for KerraMax dressing
This article was originally published in Clinica
Executive Summary
Ark Therapeutics has gained reimbursement approval from the UK’s National Health Service (NHS) for its KerraMax absorbent dressing. KerraMax, which is expected to make its market debut on November 1, is used for the management of leg ulcers. The London-based firm said that managing and treating venous leg ulcers is estimated to cost the NHS up to £300m ($510m) each year, with the UK market for existing absorbent dressings valued at approximately £10m. Ark also recently received NHS reimbursement approval for its Neuropad test for peripheral autonomic neuropathy in the feet of diabetic patients (see Clinica No 1325 p 21).